Cytokinetics (CYTK) News Today $49.86 -1.23 (-2.41%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Cytokinetics Target of Unusually Large Options Trading (NASDAQ:CYTK)November 21 at 1:47 AM | americanbankingnews.comCytokinetics, Bayer in Japan Licensing Pact for AficamtenNovember 20 at 7:14 PM | marketwatch.comCytokinetics’ Hold Rating Amid Bayer Partnership and Acquisition UncertaintyNovember 20 at 2:14 PM | markets.businessinsider.comCytokinetics Gains ‘Buy’ Rating Due to Strategic Collaborations and Potential FDA ApprovalNovember 20 at 9:11 AM | markets.businessinsider.comNeedham & Company LLC Reaffirms "Buy" Rating for Cytokinetics (NASDAQ:CYTK)Needham & Company LLC reaffirmed a "buy" rating and issued a $72.00 target price on shares of Cytokinetics in a research note on Wednesday.November 20 at 8:19 AM | marketbeat.comCytokinetics, Incorporated (NASDAQ:CYTK) CEO Sells $252,750.00 in StockNovember 20 at 5:47 AM | insidertrades.comRoyce & Associates LP Has $1.28 Million Holdings in Cytokinetics, Incorporated (NASDAQ:CYTK)Royce & Associates LP raised its position in Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 70.2% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 24,250 shares of the biopharmaceutical company's stock after purNovember 20 at 3:59 AM | marketbeat.comCytokinetics and Bayer Partner to Expand Aficamten's Reach in JapanNovember 19 at 5:16 PM | finance.yahoo.comCytokinetics partnership demonstrates value of aficamten, says JMP SecuritiesNovember 19 at 5:16 PM | markets.businessinsider.comCytokinetics Secures Strategic Licensing Deal with Bayer, Boosting Global Prospects for AficamtenNovember 19 at 5:16 PM | markets.businessinsider.comFirst Turn Management LLC Decreases Stake in Cytokinetics, Incorporated (NASDAQ:CYTK)First Turn Management LLC lowered its holdings in Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 23.9% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 223,147 shares of the biopharmaceutical company's stocNovember 19 at 6:08 AM | marketbeat.comBayer acquires rights to Cytokinetics' heart drug in JapanNovember 19 at 3:26 AM | reuters.comCytokinetics and Bayer Announce Exclusive Licensing Collaboration for Aficamten in JapanNovember 19 at 2:30 AM | globenewswire.comCytokinetics' (CYTK) "Buy" Rating Reaffirmed at HC WainwrightHC Wainwright restated a "buy" rating and set a $120.00 price target on shares of Cytokinetics in a research report on Monday.November 18 at 8:11 AM | marketbeat.comCytokinetics, Incorporated (NASDAQ:CYTK) Given Consensus Recommendation of "Moderate Buy" by BrokeragesNovember 18 at 3:05 AM | americanbankingnews.comCytokinetics Presents Additional Data From GALACTIC-HF at the American Heart Association Scientific Sessions 2024November 16, 2024 | globenewswire.comCytokinetics Presents New Data Relating to Aficamten and Hypertrophic Cardiomyopathy at the American Heart Association Scientific Sessions 2024November 16, 2024 | globenewswire.comPrincipal Financial Group Inc. Sells 120,497 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK)Principal Financial Group Inc. lowered its stake in Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 30.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 273,082 shares of the biopharmaceutical companNovember 16, 2024 | marketbeat.comCytokinetics: On The Cusp Of CommercializationNovember 14, 2024 | seekingalpha.comCytokinetics, Incorporated (NASDAQ:CYTK) EVP Fady Ibraham Malik Sells 6,342 SharesNovember 14, 2024 | insidertrades.comCytokinetics, Incorporated (NASDAQ:CYTK) Receives Average Rating of "Moderate Buy" from AnalystsCytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the sixteen brokerages that are covering the company, MarketBeat Ratings reports. Four investment analysts have rated the stock with a hold recommendation and twelve have givenNovember 13, 2024 | marketbeat.comFMR LLC Bolsters Stake in Cytokinetics IncNovember 12, 2024 | gurufocus.comCytokinetics to Participate in the 2024 Jefferies London Healthcare ConferenceNovember 12, 2024 | uk.finance.yahoo.comCytokinetics (CYTK) Initiated with a Buy at RBC CapitalNovember 12, 2024 | markets.businessinsider.comCytokinetics, Incorporated: Cytokinetics Announces Initiation of Phase 1 Clinical Study of CK-4015089November 12, 2024 | finanznachrichten.deCytokinetics announces initiation of Phase 1 study of CK-089November 12, 2024 | markets.businessinsider.comCytokinetics’ Promising Future: Buy Rating Backed by Strong Pipeline and Strategic PositioningNovember 12, 2024 | markets.businessinsider.comLisanti Capital Growth LLC Sells 26,800 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK)Lisanti Capital Growth LLC lessened its holdings in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 68.4% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 12,355 shares of the biopharmaceutical company's stocNovember 12, 2024 | marketbeat.comCytokinetics (NASDAQ:CYTK) Now Covered by Royal Bank of CanadaNovember 12, 2024 | americanbankingnews.comCytokinetics FY2024 EPS Estimate Lowered by HC WainwrightNovember 12, 2024 | americanbankingnews.comCytokinetics Announces Initiation of Phase 1 Clinical Study of CK-4015089November 11, 2024 | globenewswire.comCytokinetics: Strategic Growth and Strong Financial Positioning Drive Buy RatingNovember 11, 2024 | markets.businessinsider.comFY2024 EPS Estimates for Cytokinetics Cut by HC WainwrightCytokinetics, Incorporated (NASDAQ:CYTK - Free Report) - HC Wainwright lowered their FY2024 earnings estimates for Cytokinetics in a note issued to investors on Thursday, November 7th. HC Wainwright analyst J. Pantginis now forecasts that the biopharmaceutical company will earn ($5.39) per shareNovember 11, 2024 | marketbeat.comVan ECK Associates Corp Acquires 12,565 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK)Van ECK Associates Corp lifted its stake in Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 21.3% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 71,691 shares of the biopharmaceutical company's sNovember 10, 2024 | marketbeat.comThis Cytokinetics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For FridayNovember 9, 2024 | benzinga.comCytokinetics (NASDAQ:CYTK) Stock Quotes, Forecast and News SummaryNovember 9, 2024 | benzinga.comRBC Capital Initiates Coverage of Cytokinetics (CYTK) with Outperform RecommendationNovember 9, 2024 | msn.comCytokinetics (NASDAQ:CYTK) Earns Outperform Rating from Analysts at Royal Bank of CanadaRoyal Bank of Canada initiated coverage on Cytokinetics in a research report on Friday. They issued an "outperform" rating and a $80.00 target price on the stock.November 8, 2024 | marketbeat.comCytokinetics initiated with an Outperform at RBC CapitalNovember 8, 2024 | markets.businessinsider.comCytokinetics Hold Rating: Balancing Progress and Challenges Amid Uncertain UpsideNovember 7, 2024 | markets.businessinsider.comBarclays Sticks to Its Buy Rating for Cytokinetics (CYTK)November 7, 2024 | markets.businessinsider.comCytokinetics (NASDAQ:CYTK) Posts Earnings Results, Misses Estimates By $0.09 EPSCytokinetics (NASDAQ:CYTK - Get Free Report) announced its quarterly earnings data on Wednesday. The biopharmaceutical company reported ($1.36) earnings per share for the quarter, missing analysts' consensus estimates of ($1.27) by ($0.09). The firm had revenue of $0.46 million during the quarter, compared to analyst estimates of $1.21 million. During the same quarter in the previous year, the company earned ($1.35) earnings per share. The business's revenue for the quarter was up 22.5% on a year-over-year basis.November 7, 2024 | marketbeat.comCytokinetics Inc (CYTK) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial ...November 7, 2024 | gurufocus.comCytokinetics, Incorporated (CYTK) Q3 2024 Earnings Call TranscriptNovember 6, 2024 | seekingalpha.comCytokinetics Announces Six Upcoming Presentations at the American Heart Association Scientific Sessions 2024November 6, 2024 | markets.businessinsider.comCytokinetics Reports Third Quarter 2024 Financial ResultsNovember 6, 2024 | globenewswire.comInternational Assets Investment Management LLC Takes Position in Cytokinetics, Incorporated (NASDAQ:CYTK)International Assets Investment Management LLC acquired a new stake in Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 10,560 shares of the biopharmaceutical companyNovember 6, 2024 | marketbeat.comEarnings To Watch: Cytokinetics Inc (CYTK) Reports Q3 2024 ResultNovember 5, 2024 | finance.yahoo.comAlphaCentric Advisors LLC Acquires New Position in Cytokinetics, Incorporated (NASDAQ:CYTK)AlphaCentric Advisors LLC bought a new position in Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 12,500 shares of the biopharmaceuticalNovember 5, 2024 | marketbeat.comCytokinetics, Incorporated (NASDAQ:CYTK) CEO Robert I. Blum Sells 5,000 SharesNovember 5, 2024 | insidertrades.com Get Cytokinetics News Delivered to You Automatically Sign up to receive the latest news and ratings for CYTK and its competitors with MarketBeat's FREE daily newsletter. Email Address This Bull Market Indicator called NVDA at $116 (Ad)Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run… All you have to do is follow this link here CYTK Media Mentions By Week CYTK Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CYTK News Sentiment▼0.410.45▲Average Medical News Sentiment CYTK News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CYTK Articles This Week▼2410▲CYTK Articles Average Week Get Cytokinetics News Delivered to You Automatically Sign up to receive the latest news and ratings for CYTK and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ORIC Pharmaceuticals News Phathom Pharmaceuticals News Nkarta News Karyopharm Therapeutics News BioXcel Therapeutics News Teva Pharmaceutical Industries News BeiGene News Viatris News Summit Therapeutics News Moderna News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CYTK) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cytokinetics, Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Cytokinetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CYTK Stock Alerts